Loading…

TriMas CorporationTRSCompetitor analysis, valuation and peers

United States · USD·Materials›Containers/Packaging

Diversified industrial maker of specialty packaging closures, aerospace fasteners and engineered products.

Momentum neutral 45
Mkt cap
$1.37B
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$16.2M
20-day average traded
Fwd P/E
19.1×
forward earnings
ROIC−WACC
-4.0 pp
WACC 7.3%
Hurdle
n/a
no reverse DCF
Official | Implied
B / BB-
agencies · bond market
Next earnings
118 days
4 Mar 2027
Close · USD$38.61
1D+2.0%
1W+1.2%
1M+0.4%
3M-3.5%
6M-9.6%
YTD+8.9%
1Y+18.3%
ATR %3.0%
Beta0.81
52w lowhigh15.0% off high

What TriMas does

Diversified industrial maker of specialty packaging closures, aerospace fasteners and engineered products.

Sells components that are specified into customer products, so closures and fasteners are reordered for years after a design win. Aerospace fastener sales follow aircraft build rates, and packaging closures serve industrial and chemical containers.

Products and services

  • Packaging closures/dispensing (Rieke)
  • Aerospace fasteners (Monogram)
  • Specialty engineered products

Customers

  • Industrial/chemical packagers
  • Aerospace OEMs
  • Consumer products companies

Where it sits in the supply chain

  • Materials/Industrials
  • Specialty packaging and fasteners…
  • Industrial/aerospace supply

What could go right

  • Aerospace build-rate recovery
  • Industrial packaging demand

What could go wrong

  • Aerospace cycle exposure
  • Industrial end-market cyclicality

Moat: narrow (switching costs, process know-how). Qualified aerospace fastener designs and packaging closure specs are costly for customers to re-source.

Headquarters: Bloomfield Hills, Michigan, US · Founded: 1988 · Employees: 3,700

Named competitors

TriMas at a glance

Size TriMas (TRS) is a United States Materials company (Containers/Packaging) with a market value of $1.37B, the 2054th largest of 3,117 United States companies the cockpit tracks. Shares closed at $38.61 on 6 Nov 2026.

Performance Over six months the shares fell 9.6%, against -10.5% for the median peer and -1.1% for the United States market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue fell 33.2% over the last twelve months (peer median +1.9%); the operating margin is 4.5% (peer median 6.5%).

Valuation It trades at 19.1× forward earnings against a peer median of 15.8× (8th most expensive of 20).

Capital Return on invested capital runs 4.0 points below its cost of capital (7.3% WACC).

Credit TriMas has 1 bond outstanding ($400M), rated B by the agencies and trading like BB- at a weighted spread of 194 bp.

Short interest Short interest is 9.4% of the free float (15 Oct 2026).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011011 May 202611 Aug 20266 Nov 2026TRS 93Peer median 88
Six months, rebased to 100: TriMas against the median of its 20 peers (local-currency closes).

TriMas financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$677M$646M$631M$894M$884M
Revenue growth—+2%-29%+1%—
Gross profit$180M$131M$123M$195M$194M
EBITDA$78.6M$71.1M$85.7M$135M$135M
Net income$915M$120M$24.2M$40.4M$66.2M
Free cash flow-$108M$69.1M$12.8M$34.0M$26.6M
Capital expenditure$24.9M$48.4M$51.0M$54.2M$46.0M
Total debt$436M$505M$434M$443M$444M

Quarterly statements and history in the cockpit →

TriMas competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%-10%0%+10%ORA002243002565301093300151600210002969GXI7864CAS0027010027879939002014600529ELO603687WPK603091002803TRS6-month return →1-month return →
Up and to the right = strong over both horizons. TriMas is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%25×50×75×ORA002243301093300151600210002969GXI7864CAS002701002787600529603687603091002803TRSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. TriMas is the large dot.

TriMas competitors and peer comparison

Head to head with its named competitors (TRS vs ATR vs SLGN vs TDG)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
TriMas TRS$1.37B-10%-33%5%19.1×n/a
AptarGroup ATR$9.03B+18%+9%12%23.4×4.3%
Silgan SLGN$4.34B+2%+4%10%10.2×-5.8%
TransDigm TDG$66.2B-1%+17%47%25.5×9.7%

How TriMas compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TriMas against its 20 peers (data as of 6 Nov 2026)
MeasureTRSPeer medianRank in peer set
1-month return+0.4%0.0%10th highest of 21
6-month return-9.6%-10.5%10th highest of 21
Distance from 52-week high-15.0%-33.5%6th highest of 21
Revenue growth (TTM)-33.2%+1.9%lowest of 21
Operating margin4.5%6.5%5th lowest of 21
Forward P/E19.1×15.8×8th most expensive of 20
ROIC minus cost of capital-4.0 pp+0.8 pp6th lowest of 21
EV / EBITDA8.3×6.8×most expensive of 8
Net debt / EBITDA-9.2×2.2×least indebted of 8
Bond spread194 bpn/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
TriMas TRSUnited States$1.37B-10%-33%5%19.1×n/an/a
Orora ORA.AXAustralia$1.34B+17%+6%11%15.8×2.5%-8.9%
Shenzhen Leaguer 002243.SZChina$1.27B-18%+5%-3%19.9×44.6%+1.6%
Shanghai Shunho New Materials Technology 002565.SZChina$1.51B-50%-15%-3%n/an/an/a
Jiangsu Hualan New Pharmaceutical Material 301093.SZChina$1.53B-27%+6%5%77.4×50.9%+6.7%
Shenzhen Changhong Technology 300151.SZChina$1.23B-12%-1%6%59.9×n/an/a
Shanghai Zijiang Enterprise 600210.SSChina$1.54B-3%-18%10%11.3×n/an/a
Jiamei Food Packaging (Chuzhou) 002969.SZChina$1.55B-56%-10%6%86.4×22.4%+7.3%
Gerresheimer GXI.DEGermany$1.21B+24%+9%-4%18.0×55.8%+10.3%
Fuji Seal International 7864.TJapan$1.18B+38%+4%9%10.8×-9.5%+5.9%
Cascades CAS.TOCanada$1.15B+49%+1%5%9.2×-1.9%+3.1%
ORG Technology 002701.SZChina$1.65B-22%+24%5%9.6×-5.2%+15.8%
Suzhou Hycan 002787.SZChina$1.09B-10%0%7%36.4×n/an/a
Taiwan Hon Chuan Enterprise 9939.TWTaiwan$1.07B+7%0%15%10.2×n/an/a
Huangshan Novel 002014.SZChina$1.02B+5%+9%12%15.7×n/an/a
Shandong Pharmaceutical Glass 600529.SSChina$1.85B0%-9%18%16.5×-2.4%+5.5%
Elopak ELO.OLNorway$1.01B-11%0%9%11.8×-8.3%+7.7%
Zhejiang Great Shengda Packing 603687.SSChina$995M-30%+1%3%32.6×n/an/a
Winpak WPK.TOCanada$1.91B+12%+3%15%12.5×-10.9%+6.6%
Zhejiang Zhongxin Environmental Protection Technology 603091.SSChina$991M-20%+31%22%14.5×7.8%+4.4%
Xiamen Jihong 002803.SZChina$956M-16%+12%6%21.3×6.4%+8.8%

TriMas bonds and credit

TriMas has 1 bond outstanding with $400M face value. The agencies rate it B; its bonds trade like BB-. Weighted yield 6.44%, a spread of 194 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are TriMas's main competitors?
Named competitors: AptarGroup (ATR), Silgan Holdings (SLGN), TransDigm (TDG). The cockpit's measured peer set (industry) also includes Orora (ORA.AX), Shenzhen Leaguer (002243.SZ), Shanghai Shunho New Materials Technology (002565.SZ), Jiangsu Hualan New Pharmaceutical Material (301093.SZ), Shenzhen Changhong Technology (300151.SZ), Shanghai Zijiang Enterprise (600210.SS).
Is TriMas expensive compared with its peers?
On forward p/e it trades at 19.1× against a peer median of 15.8×, 8th most expensive of 20 in its peer set.
How has TriMas stock performed?
Over six months to 6 Nov 2026 the shares returned -9.6% against -10.5% for the median peer; over one year +18.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.